Dr Kathleen N Moore shares her perspectives on the evolving therapeutic landscape for patients with gynecologic cancers.

Dr Angeles Alvarez Secord from the Duke Cancer Institute in Durham, North Carolina, provides her perspectives on recent datasets from ASCO 2024 on the management of ovarian and endometrial cancers.

Dr Dana M Chase from the David Geffen School of Medicine at UCLA in Los Angeles, California, discusses select 2023 data sets on the management of ovarian, endometrial and cervical cancers.

Dr Bradley J Monk from the Florida Cancer Specialists & Research Institute in West Palm Beach, Florida, discusses real-world patient cases and treatment strategies for ovarian cancer.

Dr Antonio González-Martín from the Clínica Universidad de Navarra in Madrid, Spain, discusses real-world patient cases and treatment strategies for ovarian cancer.

Dr David M O’Malley from The Ohio State University and the James Comprehensive Cancer Center in Columbus, Ohio discusses the role of HER2-directed therapy in the treatment of gynecologic cancers.

Dr Richard Penson from Massachusetts General Hospital in Boston, Massachusetts and Dr Krishnansu Tewari from the University of California, Irvine, discuss updated data from the 2023 ESMO Congress on optimal management approaches for gynecologic cancers.

Dr David M O’Malley from the Ohio State University and the James Cancer Center in Columbus, Ohio, discusses optimizing the management of ovarian cancer.

Dr Kathleen Moore from OU Health Stephenson Cancer Center in Oklahoma City discusses treatment decision-making for real-world cases and approved and investigational treatment strategies for the management of ovarian cancer.

Dr Debra L Richardson from OU Health Stephenson Cancer Center in Oklahoma City discusses novel agents and strategies for ovarian cancer.